Background And Objective: The quality of life of persons with dementia and their relatives crucially depends on whether they succeed in establishing a stable home care situation. In this study, an outreach dyadic support program for persons with dementia and relatives was carried out by dementia nursing experts (DNE) for the first time. The aim of the nurse-led dyadic support program focuses on the lifeworld benefits for dyads and the benefits towards coping with dementia and crisis management in their home environment. Does it turn out to be a suitable offer for dyads in rural areas? Could the program originally developed for therapists be carried out by DNE?

Methods: Using an interview guideline, 12 episodic interviews were conducted with dyads and additionally two focus groups (n = 5 relatives and n = 2 dementia nursing experts). The interviews were recorded, transcribed verbatim and analyzed using content analysis.

Results: The results of a qualitative evaluation with a multiperspective approach are presented. The participating dyadic benefit depends on several factors, e.g. dyadic relationship, stage of dementia, in different ways. The outreach approach is therefore important. The dyadic setting is mostly seen as helpful, a need for additional one-to-one meetings is desired. The program can be used by DNE, the shift can even be an advantage. It is questionable whether temporary support lasts over the entire course of the disease.

Conclusion: The results show that home care situations can be improved for dyads through the nurse-led program, they can even benefit by DNE. The possibility of one-to-one meetings and follow-up care should be given. The outreach approach is crucial for rural areas. The results point to the need for more outreach care for persons with dementia in order to reduce stress and strengthen identity and action resources.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10589127PMC
http://dx.doi.org/10.1007/s00391-022-02106-7DOI Listing

Publication Analysis

Top Keywords

persons dementia
16
dyadic support
12
support program
12
dementia relatives
12
dementia nursing
12
nursing experts
12
dementia
9
program persons
8
outreach approach
8
one-to-one meetings
8

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Signant Health, Blue Bell, PA, USA.

Background: In Alzheimer's Disease trials, the Mini-Mental State Examination (MMSE) and Clinical Dementia Rating (CDR) are commonly utilized as inclusionary criteria at screening. These measures, however, do not always reaffirm inclusionary status at baseline. Score changes between screening and baseline visits may imply potential score inflation at screening leading to inappropriate participant enrollment.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Background: The ability to monitor cognitive trajectories over the course of trials can provide valuable insights into treatment efficacy. However, existing trial methods are limited in monitoring cognition in real-time and at high frequencies. Gameplay-based assessments hold promise as complementary cognitive tools.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Sharp Therapeutics, Pittsburgh, PA, USA.

Background: Progranulin (GRN) plays a critical role in familial frontotemporal dementia (fFTD), where GRN haploinsufficiency leads to reduction in PGRN levels in the brain, resulting in degeneration of neurons in the frontal lobe of brain responsible for personality, language, and behavior. FTD is the most common dementia in people under 60. Sortilin (Sort1), expressed by neurons, endocytoses, and delivers PGRN rapidly to lysosomes for degradation.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

NA, Charlottesville, VA, USA.

Preclinical Alzheimer's prevention trials require a multi-year commitment from diverse, cognitively unimpaired individuals willing to receive biomarker results of confirmed Alzheimer's pathology and possible ApoE4 status. Participants learn new terms such as ARIA, edema and microhemorrhage and undergo numerous MRI scans for safety monitoring. They take quarterly composite Alzheimer's assessments that are anxiety-provoking and highlight weaknesses which may have been unrecognized in daily life.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Massachusetts General Hospital, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Preclinical Alzheimer's disease (AD) trials can involve multiple years of follow-up and burdensome procedures for older individuals. Optimizing the design and conduct of these trials requires input from participants and their families. Since 2020, the Alzheimer's Clinical Trials Consortium (ACTC) Research Participant Advisory Board has provided input on study attributes including: participant and study partner compensation, consent language, and result communication tools.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!